Clinical trial transparency is a key priority of the new Executive Director of the European Medicines Agency (EMA), Professor Guido Rasi.

In a press briefing on Wednesday 9th December Professor Rasi outlined his vision for his five-year mandate as Executive Director. He highlighted transparency as a key aspect of the EMA’s approach moving forward.

On the EMA’s commitment to transparency, Professor Rasi said:

“We have a pioneering approach to transparency. We are the first regulator in the world to allow researchers and academics, and the public as a whole, access to the clinical data on which marketing authorisations are based.”

In addition to transparency, the EMA want to ensure the best use of all available evidence. With the European population exceeding 500 million citizens, Professor Rasi pointed out that there are enormous opportunities to study the impact of medicines in real life and monitor their safety and efficacy.